Advertisement
Advertisement
April 13, 2026
Microbot Liberty Endovascular Robotic System Launched With Full Market Release in the United States
April 13, 2026—Microbot Medical Inc. announced that it has executed a limited market release of the Liberty robotic system for peripheral endovascular procedures. The company will commence the full market release of the system in the United States at SIR 2026, the Society of Interventional Radiology annual scientific meeting in Toronto, Canada.
According to Microbot, the single-use, remotely operated Liberty robotic system received FDA clearance in September 2025.
It is designed for precise vascular navigation while aiming to reduce radiation exposure and physical strain, which are key clinical and operational challenges faced by interventional radiology teams, stated Microbot.
The company noted that the Liberty system has been successfully used commercially across a variety of procedures, including prostate artery embolization, uterine fibroid embolization, genicular artery embolization, yttrium-90 (Y90) mapping, Y90 deliveries, and peripheral arterial interventions.
In preparation for the FMR, Microbot advised that it has enhanced its commercial team by adding salespeople in key locations and broadening its sales footprint from four to eight sales territories, with a goal of 12 territories across the United States by the end of 2026.
Advertisement
Advertisement
